Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies.

Since its founding in 1992, Alexion has given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation. At Alexion, our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people’s lives are at stake.

Alexion has 2,500 passionate and dedicated employees serving patients in 50 countries around the world.